-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NKtPYv5gfQt4CQVDSXHe7rPTCzlJ8wfG7mfiwJf1vlUjAcywHko4+UI6uAtjoJxl qQKyFlCgPNcJMwTRIuPNJw== 0000950116-02-000020.txt : 20020413 0000950116-02-000020.hdr.sgml : 20020413 ACCESSION NUMBER: 0000950116-02-000020 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20010104 ITEM INFORMATION: Other events FILED AS OF DATE: 20020107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENEREX BIOTECHNOLOGY CORP CENTRAL INDEX KEY: 0001059784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820490211 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-25169 FILM NUMBER: 2503313 BUSINESS ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO CANA STATE: A1 BUSINESS PHONE: 4163642551 MAIL ADDRESS: STREET 1: 33 HARBOUR SQ STREET 2: STE 202 CITY: TORONTO ONTARIO M5J STATE: A1 8-K 1 eight-k.txt 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 4, 2001 ---------------- Generex Biotechnology Corporation ------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) Delaware 000-25169 98-0178636 - ----------------- ------------- ------------------- (State or other (Commission (IRS Employer jurisdiction of Incorporation) File Number) Identification No.) 33 Harbour Square, Suite 202, Toronto, Ontario Canada M5J 2G2 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code 416/364-2551 - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report) Item 5. Other Events. Effective as of January 4, 2002, the Board of Directors of Generex Biotechnology Corporation (the "Company") fixed the date, time, location and record date for the annual meeting of the stockholders of the Company for the 2001 fiscal year. The Board of Directors determined that the annual meeting of the Company will be held on Monday, March 18, 2002 at 10:00 a.m. (local time) at St. Lawrence Hall, 157 King Street East, Toronto, Ontario, Canada M5E 1C4. The Board of Directors also established the close of business on February 4, 2002 as the record date for the determination of stockholders entitled to receive notice of, and to vote at, the annual meeting and any adjournment or postponement thereof. Stockholder Proposals Any proposals of stockholders intended to be presented at the annual meeting of stockholders for fiscal year 2001 were required to be received by the Company at the principal executive offices of the Company no later than September 1, 2001 in order to be included in the proxy materials for such meeting. Such proposals were required to meet the requirements set forth in the rules and regulations of the Securities and Exchange Commission in order to be eligible for inclusion in the proxy materials for such meeting. For business to be properly brought before the annual meeting by a stockholder in a form other than a stockholder proposal, the stockholder must give timely notice of such business in writing to the Secretary of the Company. To be timely, a stockholder's notice must be delivered to or mailed and received at the principal executive offices of the Company no later than the close of business on January 18, 2002. A stockholder's notice to the Secretary must set forth the following information as to each matter the stockholder proposes to bring before the meeting: o a brief description of the business desired to be brought before the meeting and the reasons for conducting such business at the meeting; o the name and address, as they appear on the Company's books, of the stockholder proposing such business; o the class and number of shares of the Company's capital stock which are beneficially owned by the stockholder; and o any material interest of the stockholder in such business. Director Nominations A stockholder of the Company entitled to vote for the election of directors at the annual meeting may nominate a candidate for election to the Board of Directors provided the stockholder gives timely notice of his or her intention to make such nomination. The notice must be in writing to the Secretary of the Company, and must be delivered to or mailed and received at the principal executive offices of the Company no later than the close of business on January 18, 2002. The notice must set forth the following information relating to the nominee whom the stockholder proposes to nominate for election or re-election as a director: o the name, age, business address and residence address of the nominee; o the principal occupation or employment of the nominee; o the class and number of shares of the Company which are beneficially owned by the nominee; and o any other information relating to the nominee that is required to be disclosed in solicitations of proxies for the election of directors or otherwise is required pursuant to Regulation 14A under the Securities Exchange Act of 1934. In addition, the notice must set forth the following information relating to the stockholder giving the notice: o the name and address, as they appear on the Company's books, of such stockholder and o the class and number of shares of the Company which are beneficially owned by such stockholder. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENEREX BIOTECHNOLOGY CORPORATION Dated: January 7, 2002 By: /s/ E. Mark Perri --------------- ------------------------------- E. Mark Perri, Chairman and CFO -----END PRIVACY-ENHANCED MESSAGE-----